References
Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ. 2009;338:b1147.
Donegan S, Williamson P, Gamble C, Tudur-Smith C. Indirect comparisons: a review of reporting and methodological quality. PLoS One. 2010;5:e11054.
Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D’Amico R, et al. Indirect comparisons of competing interventions. Health Technol Assess. 2005;9:1–134 (iii–iv).
Villa G, Hernandez-Pastor LJ, Guix M, Lavernia J, Cuesta M. Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain. Clinical and translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2014.
Conflict of interest
J. Martin-Broto has participated, in the past, in advisorie board of GSK, AMGEN, NOVARTIS AND PHARMAMAR.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Martin-Broto, J. Indirect comparisons in cost-effectiveness analysis: are we being naïve?. Clin Transl Oncol 17, 85–86 (2015). https://doi.org/10.1007/s12094-014-1256-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-014-1256-9